mva-mosaic
Vaccineexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02218125)
Timeline
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mva-mosaic
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03307915 | Phase 1 | Mar 5, 2018 | Harvard University, Janssen Pharmaceutica NV, Ragon Institute of MGH, MIT and Harvard, United States Army |
| NCT02919306 | Phase 1/Phase 2 (Phase 2) | Sep 16, 2016 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02315703 | Phase 2 | Dec 22, 2014 | Crucell, Harvard University, International AIDS Vaccine Initiative, National Institute of Allergy and Infectious Diseases (NIAID), United States Army |
| NCT02218125 | Phase 1 | Sep 1, 2014 | Crucell, Harvard University, National Institute of Allergy and Infectious Diseases (NIAID), United States Army |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 3 | 0 | 2 | 2014 |
| United States Army | Government | 3 | 0 | 2 | 2014 |
| Crucell | For profit | 2 | 2 | 2 | 2014 |
| Janssen Pharmaceutica NV | For profit | 2 | 1 | 2 | 2016 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 0 | 2 | 2014 |
| International AIDS Vaccine Initiative | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2016 |
| Ragon Institute of MGH, MIT and Harvard | Academic/Hospital | 1 | 0 | 1 | 2018 |
8 organizations
Page 1 / 1